Press Briefing Day 2 - SATURDAY, JUNE 16, 2018


A new	anti-	CD22 CAR-T	' immunotherapy	saved the	lives of	f children	with leukem	ia
Dr Jing	g Pan.	Beijing Boren	Hospital, Beijing.	China (A	bstract	S832)		

Our study shows that CD22-CAR-T cell therapy is a highly effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and also-HCT. It gives these otherwise untreatable patients a new hope.MAIN SLIDES

iNNOVATE Study: Ibrutinib plus Rituximab for patients with Waldenström's Macroglobulinemia Dr Meletios Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece (**Abstract S852**)

Conclusion:

Based on the data from this study, ibrutinib+rituximab could become a standard treatment option for WM. MAIN SLIDES



EHA Topics-in-Focus: From the basics of sickle cell disease to where we are now Maria Cappellini, University of Milan-Foundation IRCCS Policlinico Hospital, Italy